A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

Condition:   Psoriasis Intervention:   Drug: Mirikizumab Sponsor:   Eli Lilly and Company Not yet recruiting

Source: ClinicalTrials.gov - June 14, 2018 Category: Research Source Type: clinical trials